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Abstract – The aim of this study was to investigate whether Huisheng Oral Solution has an anticoagulant effect in a rat 
model of thrombosis. Forty male SD rats were equally and randomly divided into four groups: blank group, model group, 
and two treatment groups (A and B). Rats were subcutaneously injected with carrageenan to induce thrombosis. Rats in 
treatment group A were intragastrically administered with Huisheng Oral Solution in a dose of 2 mL/100 g body weight 
(once per 8 h) 72 h after carrageenan injection, and those in treatment group B both 72 h before and after the induction of 
thrombosis. Blood samples were collected 24, 48, and 72 h after carrageenan injection for measurements of prothrombin 
time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen (FIB), pro-
thrombin activity (PTA), platelets (PLT), fibrin degradation products (FDPs), and D-dimer. Lung, liver and mesentery 
samples were taken 72 h after carrageenan injection for histopathological analysis. The number of microthrombi in sec-
tions of different tissue samples were counted under a microscope. Blood parameters among each group were compared 
using the Welch test, Kruskal-Wallis test or SNK test after testing for normality, while the number of microthrombi was 
compared using the Bonferroni test. Compared to the model group, PT, APTT, INR, and FIB levels at the majority of time 
points were significantly shorter or lower in the two treatment groups (P <0.05 for all), but the PTA was not significantly 
improved in the treatment groups. The levels of FDPs and D-dimer and PLT counts at the majority of time points were 
significantly lower (P <0.05 for all), and the numbers of microthrombi in the lung, liver and mesentery samples were 
significantly decreased (P <0.05 for all) in the two treatment groups. The above parameters at the majority of time points 
showed no significant differences between the two treatment groups. We conclude that Huisheng Oral Solution can signifi-
cantly improve coagulation parameters, fibrinolysis parameters, and PLT count, and reduce blood hypercoagulability and 
microthrombosis suggesting that Huisheng Oral Solution has an anticoagulant effect in a rat model of thrombosis. 
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INTRODUCTION
Environmental  pollution  and  population  aging  in 
modern society have greatly increased the incidence 
of malignant tumors and other diseases. Many pa-
tients with malignant tumors are in a hypercoagu-
lable  state.  Venous  thromboembolism,  pulmonary 
embolism, and mild disseminated intravascular co-
agulation (DIC) are common manifestations of a hy-
percoagulable state (Rickles et al., 1992; Buller et al., 
2007). Studies have shown that the incidence of ve-
nous thromboembolism and pulmonary embolism 
in patients with malignant tumors is approximately 
1.5% (Andreasen et al., 2012). About 25% of patients 
with thromboembolic diseases have malignant tu-
mors (Lee and Levine, 2003).1224 SHUANG-QING LIU ET AL.
Huisheng Oral Solution was developed based on 
a classical recipe called Huazheng Huisheng Dan that 
was recorded in the Detailed Analysis of Epidemic 
Warm Diseases, a medical book written in the Qing 
Dynasty. Its main ingredients include ginseng, rhizo-
ma cyperi, angelica, motherwort, rhizoma sparganii, 
trogopterus dung, turtle shell, frankincense, saffron, 
Ligusticum  wallichii,  peach  kernel,  rhubarb,  leech, 
clove, and Ferula asafoetida (Fu, 2011). Being able to 
promote the flow of Qi and blood circulation, elimi-
nate phlegm and dampness, warm Yang and dredge 
meridians, and replenish Qi and blood, Huisheng 
Oral Solution is effective and safe in the treatment 
of tumors.
Treatment  with  Huisheng  Oral  Solution  com-
bined with radiotherapy and/or chemotherapy can 
improve the quality of life and prolong survival in pa-
tients with advanced cancers. Coagulation disorders 
are  common  complications  of  malignant  tumors, 
mainly manifesting as thrombosis caused by hyper-
coagulability (Gupta et al., 2005). Huisheng Oral So-
lution contains ingredients that are able to promote 
the flow of Qi and blood circulation and can there-
fore be used to treat coagulation disorders in clinical 
practice. In this study, we investigated the effect of 
Huisheng Oral Solution on coagulation function in a 
rat model of venous thrombosis.
MATERIALS AND METHODS
Animals
Forty 7-9-week-old male Sprague-Dawley (SD) rats, 
weighing 180-220 g, were provided by the Labora-
tory Animal Center of Chinese Academy of Medical 
Sciences. The animals were raised in a temperature-
controlled room (24 ± 1°C; humidity ≥40%) on a 
12-hour light:dark cycle, with free access to food and 
water. 
Reagents and equipment
Huisheng Oral Solution (batch No. 110203) was pro-
vided by the Chengdu Diao Group Tianfu Pharma-
ceutical Co., Ltd. Carrageenan was purchased from 
Sigma-Aldrich.  The  main  equipment  used  in  this 
study included an electronic balance (BS 423S, Sarto-
rius), microscope, automatic blood analyzer (LH750, 
Beckman, USA), and automated coagulation analyz-
er (Acl-Top, IL, USA).
Animal groups
Forty SD rats were equally and randomly divided 
into four groups: blank group, model group, and two 
treatment groups (A and B). Rats in the treatment 
group A were given Huisheng Oral Solution 72 h af-
ter the induction of thrombosis, while those in group 
B were given Huisheng Oral Solution both 72 h be-
fore and after the induction of thrombosis.
Model of thrombosis
The rats were subcutaneously injected in the sole of 
the rear foot with 2% carrageenan (20 mg/mL, in 
normal saline) at a dose of 20 mg/kg of body weight. 
The rats were placed at room temperature after injec-
tion. A dark red thrombus formation area appeared 
in the tail tip of the majority of animals and gradually 
expanded toward the tail root. Approximately 48-
72 h later, the sites of thrombus formation became 
black, and the tail was shed. Pathological evaluation 
revealed the presence of great amounts of fiber and 
few white blood cells and platelets in the small tail 
veins and capillaries, nuclear condensation in vascu-
lar endothelial cells (cube-shaped), and adherence of 
neutrophils to the inner walls of the blood vessels 24 
h after carrageenan injection. At 72 h, inflammatory 
changes along with mixed thrombus formation were 
visible in bigger blood vessels. 
Treatments, measurements and histopathology
All the rats were observed for 72 h. Those in group 
A were intragastrically administered with Huisheng 
Oral Solution at a dose of 2 mL/100 g body weight 
(once per 8 h) 72 h after carrageenan injection, while 
those in treatment group B were initially given Hu-
isheng Oral Solution at the same dose 72 h before 
carrageenan injection, followed by injection 72 h af-
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lected 24, 48, and 72 h after carrageenan injection 
for routine blood tests, coagulation tests (PT, APTT, 
INR, FIB, and PTA), and measurements of D-dimer 
and fibrin degradation products (FDPs). Lung, liver 
and mesentery samples were taken 72 h after carra-
geenan injection, fixed in 10% formalin, dehydrated, 
and  embedded  in  paraffin.  Sections  (4  µm)  were 
then cut using tissue samples from the upper lobe of 
the left lung, right liver lobe and middle part of the 
mesentery, stained with hematoxylin and eosin, and 
observed  under  a  microscope.  After  choosing  the 
field that contained the maximum number of micro-
thrombi under low magnification (×10), the number 
of microthrombi was counted under high magnifica-
tion (×40). Due to specimen problems or technical 
reasons, some specimens could not meet the require-
ments of testing and some data were missing. In this 
case, new data were obtained by repeating experi-
ments in a random manner. 
Statistical analysis
Numerical data are expressed as mean ± standard 
deviation (SD). Statistical analysis was performed 
using SAS 9.1 (for analysis of blood parameters) and 
SPSS 9.1 (for analysis of the number of microthrom-
bi). Blood parameters in each group were compared 
using the Welch test, Kruskal-Wallis test or SNK test 
after testing for normality. The number of micro-
thrombi was compared using the Bonferroni test. 
P-values <0.05 were considered statistically signifi-
cant.
RESULTS
Coagulation parameters
At all three time points, PT and APTT were signifi-
cantly shorter and PTA was significantly longer in 
the model group than in the blank group (Ps <0.05 
for all, Table 1). There was no significant difference in 
INR between the blank group and the model group. 
At 48 and 72 h, FIB was significantly higher in the 
model group than in the blank group (Ps <.005 for 
both, Table 1). These data suggest that rats in the 
model group were in a hypercoagulable state.
Compared to the blank group, PT showed no 
significant differences at 24 and 48 h but was sig-
nificantly  shorter  at  72  h  in  the  two  treatment 
groups. However, PT was significantly longer at all 
three time points in the two treatment groups than 
in the model group (Ps <0.05 for both, Table 1). 
There was no significant difference in PT between 
the two treatment groups. These data suggest that 
hypercoagulable states were significantly improved 
in the two treatment groups compared to the model 
group.
Compared  to  the  blank  group,  APTT  did  not 
differ significantly at 72 h in treatment group B (P 
>0.05, Table 1) but was significantly different in the 
two treatment groups at all other time points. APTT 
at 48 and 72 h were significantly longer in the two 
treatment groups than in the model group (Ps <0.05 
for both, Table 1). In addition, APTT at 72 h were 
significantly longer in group A than in the group B.
Compared to the model group, INR did not dif-
fer significantly at 24 h in the treatment group A (P 
>0.05, Table 1), but was significantly higher in the 
two treatment groups at all other time points (Ps 
<0.05 for all, Table 1). Compared to the blank group, 
INR was significantly higher in the two treatment 
Fig. 1. Platelet counts in rats of each group. *P <0.05 vs. the blank 
group; qP <0.05 vs. the control group; nP <0.05 vs. the treatment 
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groups at all other time points except at 24 h in treat-
ment group A. There was no significant difference in 
INR between the two treatment groups.
Compared to the model group, FIB did not dif-
fer significantly at 72 h in the treatment group A and 
at 24 h in group B, but was significantly higher in 
the two treatment groups at all other time points (Ps 
<0.05 for all, Table 1). There was no significant dif-
ference in INR between the blank group and the two 
treatment groups. INR was significantly lower at 72 h 
in treatment group B than in treatment group A but 
showed no significant difference at other time points 
between the two treatment groups.
Compared to the model group, FIB was signifi-
cantly higher at 48 h in group A, but showed no sig-
nificant differences at other time points in the two 
treatment groups (Ps >0.05 for all, Table 1). FIB was 
significantly higher at all time points in the two treat-
ment groups than in the blank group. PTA was sig-
nificantly lower at 48 h in group A than in group B, 
but showed no significant difference at other time 
points between the two treatment groups.
The above results suggest that the majority of 
blood coagulation parameters were significantly im-
proved in the two treatment groups compared to the 
model group. 
Table 1. Coagulation parameters in rats of each group (mean ± SD).
Groups Time PT APTT INR FIB PTA (%)
Blank 9.14±0.30 16.09±0.87 0.87±0.02 2.81±0.72 131.40±7.24
Control
24h 7.97±0.75* 13.74±1.30* 0.84±0.03 3.51±0.82 147.70±7.44*
48h 7.31±0.22* 12.04±0.34* 0.79±0.05 4.29±0.75* 144.90±2.23*
72h 7.17±0.76* 10.96±0.71* 0.79±0.05 4.16±0.53* 150.40±29.17*
Treatment A
24h 8.88±0.56q 13.93±0.94* 1.16±0.45 2.63±0.57q 159.10±20.29*
48h 8.76±0.36q 14.36±0.79q,* 1.42±0.50q,* 2.79±0.52q 155.80±6.12q,*
72h 8.53±0.41q,* 15.91±3.55q,* 1.40±0.46q,* 3.39±0.37 144.30±8.07*
Treatment B
24h 9.00±0.44q 14.11±0.93* 1.48±0.42q,* 2.86±0.64 159.20±11.58*
48h 8.98±0.49q 14.52±0.54q,* 1.38±0.44q,* 2.39±0.28q 144.90±7.36n,*
72h 8.49±0.66q,* 15.84±1.20q,n 1.15±0.23q,* 2.53±0.59q,n 153.60±12.30*
PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; FIB: fibrinogen; PTA: pro-
thrombin activity. *P <0.05 vs. the blank group; qP <0.05 vs. the control group; nP <0.05 vs. the treatment group A.
Table 2. Fibrinolysis parameters in rats of each group (mean ± SD).
Groups Time FDPs D-Dimer
Blank 3.51±0.26  90.90±20.12
Control
24h 4.93±0.61*  147.30±27.82*
48h 5.50±0.34*  181.00±19.15*
72h 5.48±0.46*  199.10±27.12*
Treatment A
24h 4.40±0.37q,*  133.60±18.00*
48h 4.68±0.28q,*  148.00±7.20q,*
72h 3.22±0.78q   137.00±22.36q,*
Treatment B
24h  3.74±0.39q,n  124.60±16.13*
48h  3.11±0.53q,n  139.00±9.39q,*
72h 3.09±0.43q  118.70±9.78q,*
FDPs: fibrin degradation products. *P <0.05 vs. the blank group; qP <0.05 vs the control group; nP <0.05 vs. the treatment group A.ANTICOAGULANT EFFECT OF HUISHENG ORAL SOLUTION IN A RAT MODEL OF THROMBOSIS 1227
Fibrinolysis parameters
At all three time points, the levels of FDPs and D-
dimer were significantly higher in the model group 
than in the blank group (Ps <0.05 for all, Table 2), 
indicating that the fibrinolytic activity was high in 
rats in the model group. This result indirectly sug-
gests that rats of the model group were in a hyperco-
agulable state.
At all three time points, the levels of FDPs were 
significantly lower in the two treatment groups than 
in the model group (Ps <0.05 for all, Table 2). Com-
pared to the blank group, the levels of FDPs were 
Fig. 2. Histopathological changes in the lung, liver and mesentery1228 SHUANG-QING LIU ET AL.
significantly higher at 24 and 48 h in the treatment 
group A (Ps <0.05 for both, Table 2), but showed no 
significant difference at other time points in the two 
treatment groups. The levels of FDPs were signifi-
cantly lower at 24 and 48 h in group B than in group 
A (Ps <0.05 for both, Table 2).
At 48 and 72 h, the levels of D-dimer were signif-
icantly lower in the two treatment groups than in the 
model group (Ps <0.05 for all, Table 2). Compared to 
the blank group, the levels of D-dimer were signifi-
cantly higher at all time points in the two treatment 
groups (Ps <0.05 for all, Table 2). There was no sig-
nificant difference in the levels of D-dimer between 
the two treatment groups.
The above results suggest that the majority of 
fibrinolysis parameters were significantly improved 
in the two treatment groups compared to the model 
group.
Platelets
At  all  three  time  points,  platelet  counts  were 
significantly higher in the model group than in the 
blank group and two treatment groups (Ps <0.05 for 
all, Fig. 1). Compared to the blank control group, 
platelet  counts  were  significantly  higher  at  24  h, 
showed no significant difference at 48 h, and were 
significantly lower at 72 h in group A. At all three 
time points, platelet counts were significantly lower 
in group B than in the blank control group. Addi-
tionally, platelet counts were significantly lower at 24 
and 48 h in group B than in group A.
Histopathology
Seventy-two  hours  after  carrageenan  injection, 
lung, liver and mesentery tissue samples were taken, 
stained with hematoxylin and eosin, and examined 
by microscopy. Extensive microthrombus formation 
was visible in the lung, liver and mesentery of rats 
in the model group. Additionally, capillary hemor-
rhaging and interstitial neutrophile infiltration in the 
lungs, cloudy swelling, degeneration and necrosis of 
hepatocytes in local areas in the liver, as well as local 
congestion and hemorrhage in the mesentery, were 
seen in rats in the model group (Fig. 2).
We next examined the field that contained the 
maximum number of microthrombi under low mag-
nification (×10) and then counted and compared the 
number of microthrombi under high magnification 
(×40) among each group. The numbers of micro-
thrombi in the lung, liver and mesentery were signif-
icantly lower in the two treatment groups than in the 
model group. There were no significant differences in 
the numbers of microthrombi in the lung, liver and 
mesentery between the two treatment groups (Fig. 
3).
Tissue samples were taken 72 h after carrageenan 
injection, fixed, dehydrated, embedded in paraffin, 
sectioned, stained with hematoxylin and eosin, and 
examined by microscopy. Thrombus formation in the 
small blood vessels was indicated (arrows): A, lung 
of a normal rat; B, lung of a rat in the model group; 
C, liver of a normal rat; D, liver of a rat in the model 
group; E, mesentery of a normal rat; F, mesentery of 
a rat in the model group (magnification ×40).
DISCUSSION
Hypercoagulable states in patients with malignant 
Fig. 3. Comparison of the numbers of microthrombi in the liver, 
lung and mesentery of rats in each group. *P <0.05 vs. the control 
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tumors  have  become  a  hot  research  topic  in  the 
medical field. Many factors may contribute to hy-
percoagulable  states,  including  increased  levels  of 
physiological coagulation factors, increased activity 
of pathological coagulation factors, elevated fibrin 
monomer levels in blood, coagulation factor trans-
fusion, decreased ability to inhibit and eliminate ac-
tivated coagulation factors, diminished fibrinolytic 
activity,  platelet  factors,  and  other  genetic  factors 
(Geng  and  Zhang,  2008).  Hypercoagulable  states 
can be congenital, acquired, or both (Crowther and 
Kelton, 2003). For cancer patients, central venous 
catheterization,  surgery  or  chemotherapy  during 
cancer treatment may cause vascular endothelial cell 
injury, increased levels of adhesion molecules, adhe-
sion of blood cells to each other and the release of 
procoagulants,  thereby  resulting  in  the  formation 
of hypercoagulable states (Van Marion et al., 2005). 
Chemotherapy-induced  reactive  thrombocytosis  is 
also a cause of hypercoagulable states in cancer pa-
tients (Zecchina et al., 2007). A previous study has 
shown that increased blood concentrations of tissue 
factor-positive microparticles are associated with the 
pathogenesis of hypercoagulable states in cancer pa-
tients (Hron et al., 2007).
More than 90% of patients with malignant tu-
mors  have  subclinical  coagulation  disorders,  and 
many of them are in a hypercoagulable state, which 
manifests as elevated levels of FIB, PLT, coagulation 
factors V, VIII, IX and X, FDP, and plasminogen ac-
tivator inhibitor-1, and decreased levels of coagula-
tion factor inhibitors (antithrombin, protein C and 
protein S) (Rickles et al., 1992; Edwards et al., 1987; 
Sun et al., 1979). In the present study, we chose PT, 
APTT, INR, FIB and PTA to assess comprehensively 
the coagulation function changes in the subject rats. 
PT is a sensitive screening test for the extrinsic co-
agulation pathway. APTT reflects the integrity of the 
endogenous pathways of the procoagulant cascade 
(VIII,  IX,  XI).  The  INR  is  calculated  by  normal-
izing the PT ratio to the power of the international 
sensitivity index (ISI). It standardizes the PT across 
different reagents of varying sensitivity and can bet-
ter reflect the true nature of coagulation disorders. 
FIB positively correlates with whole blood viscosity, 
plasma viscosity, erythrocyte sedimentation rate and 
platelet aggregation. Elevated blood levels of FIB can 
increase blood viscosity, promote red blood cell ag-
gregation and platelet aggregation, and thereby re-
sult in the formation of hypercoagulable states and 
thrombosis.
In the five coagulation parameters detected in 
this study, approximately 66.7% (20/30) of data val-
ues in the two treatment groups were significantly 
different from those in the model group. In contrast, 
only about 20% (3/15) of data values were signifi-
cantly different between the two treatment groups.
Platelet count is also closely associated with the 
coagulation system and has been used as an impor-
tant  parameter  to  assess  coagulation  function  in 
many studies (Vilar Saavedra et al., 2011; Wang et al., 
2011; Ducloy-Bouthers, 2010; Machida et al., 2010). 
In this study, we found that platelet counts were sig-
nificantly reduced in the treatment groups compared 
to the model group. In addition, a significant differ-
ence  in  platelet  count  between  the  two  treatment 
groups was observed only at 72 h.
A hypercoagulable state is often associated with 
hyperfibrinolysis, which manifests as increased levels 
of FDPs and D-dimer. In the present study, we found 
that approximately 83.3% (10/12) of data values in 
the two treatment groups were significantly different 
from those in the model group. In contrast, only 1/3 
(2/6) of data values were significantly different be-
tween the two treatment groups.
Histopathological analysis revealed obvious vas-
cular microthrombosis in both the model group and 
the two treatment groups. However, the numbers of 
microthrombi in the lung, liver and mesentery were 
significantly lower in the two treatment groups than 
in the model group, but showed no significant differ-
ence between them.
Huisheng Oral Solution was traditionally used as 
an anticancer drug in clinical practice. There has been 
no evidence so far about whether it can improve co-
agulation or not. In this study, we found that the ma-1230 SHUANG-QING LIU ET AL.
jority of coagulation parameters (66.7%), fibrinolysis 
parameters (83.3%) and platelet counts (100%) in the 
two  treatment  groups  were  significantly  improved 
compared  to  the  model  group.  In  contrast,  there 
were no significant differences in these parameters 
between the two treatment groups. These findings 
were also confirmed by histopathological analysis.
Huisheng Oral Solution is derived from a variety 
of Chinese herbs that have antitumor effects. A previ-
ous study has found that Huisheng Oral Solution has 
significant anti-cancer effects in mice bearing trans-
planted Lewis lung carcinoma (Huang et al., 1998). 
Ma et al. (2005) found that Huisheng Oral Solution 
is beneficial in improving cellular immune function 
in elderly cancer patients. We surmise that the anti-
coagulant effect of Huisheng Oral Solution observed 
in this study may be because it contains many blood-
invigorating ingredients. Yin et al. (1980) found that 
angelica and its active ingredient, ferulic acid, could 
significantly  inhibit  thrombin-induced  platelet  ag-
gregation. Zhang et al. (1980) investigated the effect 
of motherwort on mouse platelet cAMP and cGMP 
and PGI-like substance in the rat carotid artery wall 
and found that it could significantly inhibit platelet 
aggregation. In addition, rhizoma sparganii, saffron, 
rhubarb and leech can suppress platelet aggregation, 
prolong thrombosis time, reduce blood viscosity, and 
improve microcirculation. Hirudin, the main active 
ingredient of leech, is by far the strongest natural 
thrombin inhibitor in the world and has strong an-
ticoagulant effect (Mao et al., 1998; Zou, 1994; Zhao 
et al., 2009).
In this study, we found that Huisheng Oral So-
lution could significantly reduce blood hypercoagu-
lability, microthrombosis and secondary fibrinolysis 
in a rat model of thrombosis. This may be because 
it contains a variety of ingredients that have anti-
clotting effects. However, we did not find that Huish-
eng Oral Solution had preventive effects against the 
pathogenesis of hypercoagulable states.
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